FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2138362250> ?p ?o ?g. }

• W2138362250 abstract "Abstract Background To analyze the expression at basal level of inflammation-related cytokines and chemokines and the activation status of the NF-κB pathway, together with the proliferation and apoptosis indexes in two widely used in vitro tumor models, the androgen-dependent human Prostate Cancer (PC) cell line LNCaP and the androgen-independent PC3 , and in primary cultures of human PC cells. To assess in these models and primary cultures, the effects of Serenoa repens (LSESr, Permixon®) on proliferation/apoptosis ratio, inflammation-related genes expression and NF-κB pathway activation. Methods The expression of IL-6, CCL-5, CCL-2, COX-1, COX-2, iNOS inflammation-related genes has been evaluated at the mRNA level in two in vitro human PC models (LNCaP and PC3 cell lines) and in 40 independent human prostatic primary cultures obtained from PC patients undergoing radical prostatectomy. Tissue fragments were collected from both PC lesions and normal hyperplastic tissue counterparts for each case. All cultures were treated with two different amounts of Permixon® (44 and 88 μg/ml) for different time points (16, 24, 48 and 72 hours), depending on the cell type and the assay; the expression of inflammation-related genes, cell growth (proliferation/apoptosis ratio) and NF-κB activation has been analyzed in treated and untreated cells by means of semi-quantitative RNA-PCR, cell proliferation and immunofluorescence respectively. Results We detected a significant reduction (p <0.001) in PC and normal cells proliferation due to Permixon ® treatment. This result was related to an increase of the apoptotic activity showed by an increase in the number of anti-caspase-3 fluorescent cells. Almost all the inflammation-related genes (IL-6, CCL-5, CCL-2, COX-2 and iNOS) were expressed at the basal level in in vitro cultured cells and primary cultures and down-regulated by Permixon® treatment. This treatment interfered with NF-kB activation, detecting by the translocation of more than 30% of NF-κB p65 subunit to the nucleus. Conclusions The present study confirms the expression of inflammatory pattern in PC. We showed the effect of Permixon® on down-regulation of inflammatory-related genes in cell lines and in primary cultures. The inhibitory effect of Permixon® on cell growth could be partly associated to the down-regulation of inflammatory-related genes and to the activation of NF-κB pathway in prostate tissue." @default.
• W2138362250 created "2016-06-24" @default.
• W2138362250 creator A5016331942 @default.
• W2138362250 creator A5045719432 @default.
• W2138362250 creator A5049981055 @default.
• W2138362250 creator A5057812789 @default.
• W2138362250 creator A5060000517 @default.
• W2138362250 creator A5065836656 @default.
• W2138362250 creator A5084690570 @default.
• W2138362250 creator A5004525456 @default.
• W2138362250 creator A5083785848 @default.
• W2138362250 date "2013-03-14" @default.
• W2138362250 modified "2023-10-14" @default.
• W2138362250 title "Effect of Serenoa repens (Permixon®) on the expression of inflammation-related genes: analysis in primary cell cultures of human prostate carcinoma" @default.
• W2138362250 cites W172276776 @default.
• W2138362250 cites W1970803489 @default.
• W2138362250 cites W1977648249 @default.
• W2138362250 cites W1978942158 @default.
• W2138362250 cites W1988093653 @default.
• W2138362250 cites W1990794773 @default.
• W2138362250 cites W2002037918 @default.
• W2138362250 cites W2003884207 @default.
• W2138362250 cites W2019689803 @default.
• W2138362250 cites W2026798051 @default.
• W2138362250 cites W2026923775 @default.
• W2138362250 cites W2027882565 @default.
• W2138362250 cites W2030971688 @default.
• W2138362250 cites W2036455089 @default.
• W2138362250 cites W2037877598 @default.
• W2138362250 cites W2043039461 @default.
• W2138362250 cites W2052469587 @default.
• W2138362250 cites W2055660563 @default.
• W2138362250 cites W2061497413 @default.
• W2138362250 cites W2069375457 @default.
• W2138362250 cites W2069551851 @default.
• W2138362250 cites W2075477425 @default.
• W2138362250 cites W2091841967 @default.
• W2138362250 cites W2118906709 @default.
• W2138362250 cites W2120768446 @default.
• W2138362250 cites W2134173099 @default.
• W2138362250 cites W2315613727 @default.
• W2138362250 cites W2408786077 @default.
• W2138362250 cites W4231769935 @default.
• W2138362250 doi "https://doi.org/10.1186/1476-9255-10-11" @default.
• W2138362250 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3653817" @default.
• W2138362250 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23497174" @default.
• W2138362250 hasPublicationYear "2013" @default.
• W2138362250 type Work @default.
• W2138362250 sameAs 2138362250 @default.
• W2138362250 citedByCount "21" @default.
• W2138362250 countsByYear W21383622502013 @default.
• W2138362250 countsByYear W21383622502014 @default.
• W2138362250 countsByYear W21383622502015 @default.
• W2138362250 countsByYear W21383622502017 @default.
• W2138362250 countsByYear W21383622502019 @default.
• W2138362250 countsByYear W21383622502020 @default.
• W2138362250 countsByYear W21383622502021 @default.
• W2138362250 countsByYear W21383622502022 @default.
• W2138362250 countsByYear W21383622502023 @default.
• W2138362250 crossrefType "journal-article" @default.
• W2138362250 hasAuthorship W2138362250A5004525456 @default.
• W2138362250 hasAuthorship W2138362250A5016331942 @default.
• W2138362250 hasAuthorship W2138362250A5045719432 @default.
• W2138362250 hasAuthorship W2138362250A5049981055 @default.
• W2138362250 hasAuthorship W2138362250A5057812789 @default.
• W2138362250 hasAuthorship W2138362250A5060000517 @default.
• W2138362250 hasAuthorship W2138362250A5065836656 @default.
• W2138362250 hasAuthorship W2138362250A5083785848 @default.
• W2138362250 hasAuthorship W2138362250A5084690570 @default.
• W2138362250 hasBestOaLocation W21383622501 @default.
• W2138362250 hasConcept C121608353 @default.
• W2138362250 hasConcept C126322002 @default.
• W2138362250 hasConcept C142724271 @default.
• W2138362250 hasConcept C170493617 @default.
• W2138362250 hasConcept C190283241 @default.
• W2138362250 hasConcept C2776438761 @default.
• W2138362250 hasConcept C2776914184 @default.
• W2138362250 hasConcept C2779428903 @default.
• W2138362250 hasConcept C2779723316 @default.
• W2138362250 hasConcept C2780192828 @default.
• W2138362250 hasConcept C502942594 @default.
• W2138362250 hasConcept C54355233 @default.
• W2138362250 hasConcept C55493867 @default.
• W2138362250 hasConcept C62112901 @default.
• W2138362250 hasConcept C71924100 @default.
• W2138362250 hasConcept C86803240 @default.
• W2138362250 hasConcept C88045685 @default.
• W2138362250 hasConceptScore W2138362250C121608353 @default.
• W2138362250 hasConceptScore W2138362250C126322002 @default.
• W2138362250 hasConceptScore W2138362250C142724271 @default.
• W2138362250 hasConceptScore W2138362250C170493617 @default.
• W2138362250 hasConceptScore W2138362250C190283241 @default.
• W2138362250 hasConceptScore W2138362250C2776438761 @default.
• W2138362250 hasConceptScore W2138362250C2776914184 @default.
• W2138362250 hasConceptScore W2138362250C2779428903 @default.
• W2138362250 hasConceptScore W2138362250C2779723316 @default.
• W2138362250 hasConceptScore W2138362250C2780192828 @default.
• W2138362250 hasConceptScore W2138362250C502942594 @default.
• W2138362250 hasConceptScore W2138362250C54355233 @default.
• W2138362250 hasConceptScore W2138362250C55493867 @default.

• next